Аннотация:Overexpression of epidermal growth factor receptor (EGFR) and its mutations influence signal pathwaysleading to the proliferation, invasion, and increased survival of tumor cells. Despite the successful clinicalapplication of antibodies against EGFR in patients with colorectal cancer and squamous cell carcinoma ofthe head and neck, these have been found to have low efficacy in glioblastoma. The treatment of gliomastherefore requires an EGFR-specific drug able to penetrate the tumor focus in the brain and which has lowimmunogenicity. We report here studies of aptamers (single-stranded DNA oligonucleotides) specific toEGFR, U2, and Gol1 and discuss their use as agents of this type. The work reported here includes prepa-ration of a cell model of human glioma with overexpression of EGFR and EGFRvIII and its use to demon-strate the specificity of aptamers U2 and Gol1 to these receptors using classical methods and by apta-im-munocytochemistry. Investigation of the effect of binding of aptamer Gol1 to the EGFRvIII receptor onsubsequent steps in the signal pathway demonstrated changes in the levels of expression of genes associatedwith cell proliferation and survival [Jun, Fos, CCND1, PI3K and Akt3], while aptamer U2 did not produceany significant effect on cells in vitro. These results indicate that Gol1 aptamer has therapeutic potentialagainst human glioblastoma tumor cells overexpressing the mutant EGFRvIII receptor.